Identification of a Risk Signature and Immune Cell Infiltration Based on Extracellular Matrix-Related lncRNAs in Lung Adenocarcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study identifies 8 key long noncoding RNAs (lncRNAs) associated with the extracellular matrix (ECM) to predict survival in lung adenocarcinoma (LUAD) patients. These findings offer new insights for LUAD prognosis and treatment strategies.
Area Of Science
- Oncology
- Genomics
- Bioinformatics
Background
- Lung adenocarcinoma (LUAD) is a leading cause of cancer mortality, with prognosis often linked to late diagnosis.
- The extracellular matrix (ECM) significantly influences cancer cell behavior and progression.
- Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.
Purpose Of The Study
- To screen extracellular matrix-associated lncRNAs (ECM-lncRNAs) for prognostic significance in LUAD.
- To develop a robust prognostic model for predicting patient survival in LUAD.
- To explore the relationship between ECM-lncRNAs, tumor microenvironment, and potential therapeutic targets.
Main Methods
- Analysis of The Cancer Genome Atlas (TCGA) LUAD cohort using RNA-seq data.
- Application of univariate Cox, LASSO regression, and multivariate Cox analyses to identify prognostic lncRNAs.
- Construction of a prognostic signature and nomogram for survival prediction, validated by Kaplan-Meier and ROC curves.
Main Results
- Identification of 427 ECM-associated lncRNAs, with 8 selected to form a prognostic risk signature.
- The developed signature accurately predicted overall survival (OS) in LUAD patients.
- Enrichment analysis revealed involved biological processes, and correlations with tumor microenvironment (TME) and tumor mutation burden (TMB) were established.
Conclusions
- A novel prognostic signature based on 8 ECM-lncRNAs effectively predicts survival in LUAD patients.
- The signature provides valuable insights into LUAD pathogenesis and potential therapeutic strategies.
- Potential drug sensitivities, including to afatinib and crizotinib, were identified for LUAD treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...